Raymond James Upgrades Knight Therapeutics (TSE:GUD) to “Moderate Buy”

Raymond James upgraded shares of Knight Therapeutics (TSE:GUD) to a moderate buy rating in a report issued on Friday,Zacks.com reports. Raymond James also issued estimates for Knight Therapeutics’ Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

Several other equities analysts have also commented on the stock. Stifel Canada upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th. Stifel Nicolaus upgraded shares of Knight Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the company from C$5.75 to C$6.75 in a report on Tuesday, August 13th.

Knight Therapeutics Trading Down 0.6 %

GUD opened at C$5.19 on Friday. The company has a debt-to-equity ratio of 7.62, a quick ratio of 1.79 and a current ratio of 3.41. Knight Therapeutics has a one year low of C$5.07 and a one year high of C$6.23. The company has a market cap of C$525.28 million, a P/E ratio of -25.95, a PEG ratio of -1,013.50 and a beta of 0.50. The business’s 50-day simple moving average is C$5.71 and its 200-day simple moving average is C$5.73.

Insider Activity

In other news, Director Samira Sakhia purchased 20,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were acquired at an average cost of C$5.15 per share, for a total transaction of C$103,000.00. Also, insider Sime Armoyan acquired 90,300 shares of Knight Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average price of C$5.13 per share, with a total value of C$463,672.44. Corporate insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.